JT - Antibody Structure, Function & Engineering Flashcards

1
Q

What are some examples of anticancer antibody drugs? (3)

A
  • Rituximab (Rituxan)
  • Bevacizumab (Avastin)
  • Trastuzumab (Herceptin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is an example of a human antibody therapeutic?

A

Adalimumab (Humira)

A fully human antibody that targets TNFα

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the main components of an antibody? (2)

A
  • 2 light chains and 2 heavy chains
  • Linked by covalent (S-S bridges) and non-covalent interactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the functional regions of an antibody? (2)

A
  • Variable (V) region → Responsible for antigen binding
  • Constant (C) region → Responsible for effector functions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the loop that binds the antigen?

A
  • The Complementarity-Determining Region (CDR)

First point of contact

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are some key features of antibody-based biologics? (7)

A
  • Can exist in various shapes and formats
  • Can be adapted to bind to ligands in an appropriate way
  • May be used as full antibodies or as fragments
  • Monoclonal antibodies - full IgG molecules mostly
  • Murine antibodies - derived from mice
  • Have the technology to make human antibodies
  • Can take elements of an IgG molecule
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is an example of an antibody-based biologic? (3)

A

Etanercept

  • Uses the constant region of an IgG antibody and the TNF receptor
  • Used to treat autoimmune inflammatory diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Certolizumab Pegol, and how does it work? (2)

A
  • A monoclonal antibody fragment
  • Uses variable domains to bind specifically to its target
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the key components of an antibody? (4)

A
  • 2 light chains and 2 heavy chains
  • Linked by covalent (S-S bridges) and non-covalent forces
  • Variable (V) region – Binds to antigen
  • Constant (C) region – Responsible for effector functions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Where is the antigen-binding site located and what is the first point of contact? (2)

A
  • The Variable region (V region)
  • Complementarity-Determining Regions (CDRs) - The loop that binds the antigen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the steps in antibody gene recombination at the DNA level? (4)

A

Germline DNA organisation – Separate V (Variable), D (Diversity), J (Joining), and C (Constant) segments

Somatic recombination – DNA segments are cut and pasted

  • Light chain: V joins to J
  • Heavy chain: D joins to J, then V joins to DJ
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens at the RNA level? (2)

A
  • Transcription – Rearranged DNA is transcribed into RNA (primary transcript)
  • Splicing – Non-coding regions (introns) are removed, and exons are joined (mature mRNA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What happens at the protein level?

A
  • Translation – mRNA is translated into light and heavy chain polypeptides
  • Assembly – Polypeptides fold and form antigen-binding site and a complete antibody
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the main features of the light chain? (3)

A
  • Variable, Joining, and Constant domains
  • Come in 2 types: kappa (κ) (more common) and lambda (λ)
  • 70 V, 5κ and 4λ J segments
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the main features of the heavy chain? (4)

A
  • Variable, Diversity, Joining, and Constant domains
  • 40 V, 25 D, and 6 J segments
  • Allows for a vast number of different heavy chain variable regions to be generated
  • Contributes significantly to the diversity of the antibody repertoire
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the five main antibody classes?

A

Class determined by the constant region

  • IgA
  • IgD
  • IgE
  • IgG
  • IgM
17
Q

What are some key properties of different Ig classes? (5)

A
  • IgG2 - More stable hinge region than IgG1
  • IgG3 - Very long hinge region, altering function
  • IgG4 - Can form bispecific antibodies
  • IgA - mostly around mucosal surfaces; gut, lungs, tears. Forms dimer
  • IgM - First antibody generated in primary B cell response, forms pentamer
18
Q

What are some functional differences between antibody classes? (5)

A

IgM, IgG3 – Complement activation
IgG1, IgG3 – Opsonization
IgG2, IgG4 – Placental transfer
IgE – Mast cell & basophil activation
IgA – Secreted onto mucosal surfaces

19
Q

What happens when an antibody undergoes class switching? (2)

A
  • Heavy chain class changes (e.g., IgM → IgG)
  • No change in antigen specificity
20
Q

What enzyme mediates isotype switching?

A

Activation-induced cytidine deaminase (AID)

21
Q

What is somatic hypermutation? (2)

A
  • Mutations in CDR3 regions of variable domains
  • Increases antibody affinity for antigens
22
Q

What is seen in Ig levels and affinities with repeated immunisation? (6)

A

Increase in antibody concentrations (plasma)

  • Due to clonal expansion of specific B cells & memory

Increase in antibody affinities

  • Mostly seen with IgG as well as IgA, IgE
  • Secreted by switched memory B cells
  • “Affinity maturation” due to somatic hypermutation
23
Q

What is the typical half-life of IgG in humans?

24
Q

How does FcRn recycling extend IgG’s half-life? (5)

A
  • Non-specific uptake: IgG enters endothelial cells via pinocytosis, forming an endocytic vesicle (along with other proteins).
  • FcRn binding: IgG binds to FcRn receptors inside the vesicle at acidic pH.
  • Protection from degradation: FcRn binding prevents lysosomal degradation, prolonging IgG’s lifespan.
  • Recycling and release: FcRn-IgG complex is transported to the cell surface and IgG is released at neutral pH, returning to circulation.
  • Degradation (alternative pathway): If IgG does not bind FcRn, it is sent to lysosomes for degradation